ERYTECH Pharma S.A.
ERYP · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $3 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $58 | $52 |
| Gross Profit | $0 | $0 | -$58 | -$49 |
| % Margin | – | – | – | -1,451.5% |
| R&D Expenses | $20 | $45 | $58 | $52 |
| G&A Expenses | $14 | $15 | $15 | $17 |
| SG&A Expenses | $14 | $15 | $15 | $17 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$7 | -$4 | -$4 | -$5 |
| Operating Expenses | $27 | $57 | $69 | $64 |
| Operating Income | -$3 | -$57 | -$69 | $5 |
| % Margin | – | – | – | 157% |
| Other Income/Exp. Net | $3 | $3 | -$4 | -$68 |
| Pre-Tax Income | $0 | -$54 | -$73 | -$63 |
| Tax Expense | $1 | $0 | $0 | -$0 |
| Net Income | -$0 | -$54 | -$73 | -$63 |
| % Margin | – | – | – | -1,862.6% |
| EPS | -0.007 | -2.27 | -3.99 | -3.49 |
| % Growth | 99.7% | 43.1% | -14.3% | – |
| EPS Diluted | -0.007 | -2.27 | -3.99 | -3.49 |
| Weighted Avg Shares Out | 31 | 24 | 18 | 18 |
| Weighted Avg Shares Out Dil | 31 | 24 | 18 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $0 | $1 | $3 |
| Interest Expense | $1 | $2 | $5 | $2 |
| Depreciation & Amortization | -$20 | $5 | $1 | $3 |
| EBITDA | -$23 | -$46 | -$67 | $11 |
| % Margin | – | – | – | 332.3% |